Comparing two treatments for alopecia areata
Clinical Trial on the Efficacy of Intralesional Triamcinolone Versus Candida Albicans Antigen in Treating Alopecia Areata
This study is testing which of two treatments for alopecia areata, a common hair loss condition, works better for people with less than half of their scalp affected.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 6 Years and up |
| Sex | All |
| Sponsor | Universidad Autonoma de Nuevo Leon Academic / other |
| Locations | 1 site (Monterrey, Nuevo León) |
| Trial ID | NCT06564805 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the effectiveness of two intralesional treatments for alopecia areata: Triamcinolone, a standard first-line therapy, and Candida albicans antigen. The study will include thirty patients aged over 6 years with alopecia areata affecting less than 50% of the scalp. Participants will receive either treatment, and their clinical response will be monitored through serial clinical and trichoscopic evaluations. The goal is to determine which treatment is more effective and to assess any associated adverse effects.
Who should consider this trial
Good fit: Ideal candidates are patients aged over 6 with a diagnosis of alopecia areata and a SALT score indicating less than 50% scalp involvement.
Not a fit: Patients with other scalp conditions or those currently on medications that cause hair loss may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a more effective treatment option for patients suffering from alopecia areata.
How similar studies have performed: While the use of Triamcinolone is well-established, the use of Candida albicans antigen is less common, making this approach somewhat novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of alopecia areata * SALT score of less than 50% extension * Has not received any topical or systemic treatment in the last month * Signed informed consent Exclusion Criteria: * Any skin condition on the scalp (infectious, inflammatory or neoplastic) that could modify the clinical of trichoscopic features * Pregnancy or breast-feeding * Patients in medications that could cause hair loss as side-effects
Where this trial is running
Monterrey, Nuevo León
- Hospital Universitario "Dr. José Eleuterio González" — Monterrey, Nuevo León, Mexico (Recruiting)
Study contacts
- Principal investigator: Fania Muñoz Garza, PhD — Hospital Universitario "Dr. José E. González"
- Study coordinator: Erika Alba-Rojas, MD
- Email: eri9ar@yahoo.com
- Phone: +528183891111
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.